Literature DB >> 8720602

Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes.

A W Christie1, D K McCormick, N Emmison, F B Kraemer, K G Alberti, S J Yeaman.   

Abstract

Acipimox is commonly used to treat hypertriglyceridaemia in non-insulin-dependent diabetic patients, but its precise mechanism of action has yet to be elucidated. We examined the in vitro effects of acipimox on the lipolytic regulatory cascade in epididymal adipocytes isolated from Wistar rats. Acipimox inhibited the lipolytic rate stimulated by adenosine deaminase (1 U/ml) in a concentration-dependent manner, reaching a near-basal value at 10 mumol/l acipimox. Lipolysis activated by sub-maximal levels of isoproterenol in combination with adenosine deaminase (20 mU/ml) was significantly (p < 0.05) decreased by 100 mumol/l acipimox, whereas, in the absence of adenosine deaminase, 100 mumol/l acipimox showed no significant (p > 0.05) inhibition. These findings suggested that the anti-lipolytic mechanism regulated by adenosine may also be regulated by acipimox. Acipimox diminished the intracellular cyclic AMP level produced by 25 nmol/l isoproterenol in the presence of adenosine deaminase (20 mU/ml) in a concentration-dependent manner. At the same level of stimulation, acipimox inhibited the cyclic AMP-dependent protein kinase activity ratio and lipolytic rate over the same concentration range, with significant (p < 0.05) reductions occurring at and above, 0.5 mumol/l and 10 mumol/l acipimox, respectively. Western blotting showed that upon lipolytic stimulation (1 U/ml adenosine deaminase; 100 nmol/l isoproterenol) a threefold increase in the lipolytic rate was accompanied by a significant (p < 0.05) rise in hormone-sensitive lipase associated with the lipid fraction. Acipimox (1 mmol/l) and insulin (1 nmol/l) re-distributed hormone-sensitive lipase back to the cytosol, with a corresponding significant (p < 0.05) loss from the fat cake fraction of adipocyte homogenates. In conclusion, the anti-lipolytic action of acipimox is mediated through suppression of intracellular cyclic AMP levels, with the subsequent decrease in cyclic AMP-dependent protein kinase activity, leading to the reduced association of hormone-sensitive lipase with triacylglycerol substrate in the lipid droplet of adipocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8720602     DOI: 10.1007/BF00400412

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets.

Authors:  A S Greenberg; J J Egan; S A Wek; N B Garty; E J Blanchette-Mackie; C Londos
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

Review 2.  Hormone-sensitive lipase--a multipurpose enzyme in lipid metabolism.

Authors:  S J Yeaman
Journal:  Biochim Biophys Acta       Date:  1990-04-09

3.  Sensitivity of adipocyte lipolysis to stimulatory and inhibitory agonists in hypothyroidism and starvation.

Authors:  E D Saggerson
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

4.  Control of endogenous phosphorylation of the major cAMP-dependent protein kinase substrate in adipocytes by insulin and beta-adrenergic stimulation.

Authors:  J J Egan; A S Greenberg; M K Chang; C Londos
Journal:  J Biol Chem       Date:  1990-11-05       Impact factor: 5.157

5.  Detection of hormone-sensitive lipase in various tissues. I. Expression of an HSL/bacterial fusion protein and generation of anti-HSL antibodies.

Authors:  F B Kraemer; S Patel; M S Saedi; C Sztalryd
Journal:  J Lipid Res       Date:  1993-04       Impact factor: 5.922

6.  A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability.

Authors:  P Tornvall; G Walldius
Journal:  J Intern Med       Date:  1991-11       Impact factor: 8.989

7.  Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.

Authors:  G Crepaldi; P Avogaro; G C Descovich; T Di Perri; A Postiglione; C R Sirtori; A Strano; S Ventura; L Musatti
Journal:  Atherosclerosis       Date:  1988-03       Impact factor: 5.162

8.  Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM.

Authors:  G M Reaven; C Hollenbeck; C Y Jeng; M S Wu; Y D Chen
Journal:  Diabetes       Date:  1988-08       Impact factor: 9.461

9.  Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.

Authors:  L Musatti; E Maggi; E Moro; G Valzelli; V Tamassia
Journal:  J Int Med Res       Date:  1981       Impact factor: 1.671

10.  Relationship among isoproterenol, cyclic AMP, cyclic AMP-dependent protein kinase and lipolysis in perfused fat cells.

Authors:  K Sengupta; K J Long; D O Allen
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

View more
  11 in total

1.  Inhibition of adipose tissue lipolysis increases intramuscular lipid use in type 2 diabetic patients.

Authors:  L J C van Loon; R J F Manders; R Koopman; B Kaastra; J H C H Stegen; A P Gijsen; W H M Saris; H A Keizer
Journal:  Diabetologia       Date:  2005-08-12       Impact factor: 10.122

2.  Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial.

Authors:  Aaron W Aday; Allison B Goldfine; Justin M Gregory; Joshua A Beckman
Journal:  Obesity (Silver Spring)       Date:  2019-10-01       Impact factor: 5.002

3.  Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis.

Authors:  Paola Lucidi; Paolo Rossetti; Francesca Porcellati; Simone Pampanelli; Paola Candeloro; Anna Marinelli Andreoli; Gabriele Perriello; Geremia B Bolli; Carmine G Fanelli
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

Review 4.  Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.

Authors:  Helen Vosper
Journal:  Br J Pharmacol       Date:  2009-07-20       Impact factor: 8.739

5.  Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein.

Authors:  W J Shen; K Sridhar; D A Bernlohr; F B Kraemer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

Review 6.  Current and Emerging Clinical Treatment in Mitochondrial Disease.

Authors:  Rory J Tinker; Albert Z Lim; Renae J Stefanetti; Robert McFarland
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

7.  Systemic β-adrenergic stimulation of thermogenesis is not accompanied by brown adipose tissue activity in humans.

Authors:  Maarten J Vosselman; Anouk A J J van der Lans; Boudewijn Brans; Roel Wierts; Marleen A van Baak; Patrick Schrauwen; Wouter D van Marken Lichtenbelt
Journal:  Diabetes       Date:  2012-08-07       Impact factor: 9.461

8.  Metabolic disturbances due to a high-fat diet in a non-insulin-resistant animal model.

Authors:  L Ramalho; M N da Jornada; L C Antunes; M P Hidalgo
Journal:  Nutr Diabetes       Date:  2017-03-13       Impact factor: 5.097

9.  Targeting fat browning in hypermetabolic conditions: a clinical perspective.

Authors:  Supreet Kaur; Priyal Shah; Marc G Jeschke
Journal:  Future Sci OA       Date:  2020-01-21

10.  Homocysteine promotes hepatic steatosis by activating the adipocyte lipolysis in a HIF1α-ERO1α-dependent oxidative stress manner.

Authors:  Yu Yan; Xun Wu; Pengcheng Wang; Songyang Zhang; Lulu Sun; Yang Zhao; GuangYi Zeng; Bo Liu; Guoheng Xu; Huiying Liu; Lei Wang; Xian Wang; Changtao Jiang
Journal:  Redox Biol       Date:  2020-10-01       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.